Oxaliplatin and 5-Fluorouracil induce p53-p21-pRb-associated cell cycle arrest and a transient senescence-like phenotype in patient-derived low-grade serous ovarian cancer cells

Read the full article See related articles

Listed in

This article is not in any list yet, why not save it to one of your lists.
Log in to save this article

Abstract

Objectives

Low-grade serous ovarian cancer (LGSOC) is characterized by frequent TP53 wild-type status and limited responsiveness to conventional chemotherapy. This study investigated the cytotoxic effects of oxaliplatin (OXP) combined with 5-fluorouracil (5-FU) on patient-derived LGSOC cells.

Results

Clinically relevant concentrations of OXP and 5-FU had minimal effects on LGSOC cell viability but markedly reduced cellular proliferation and clonogenic recovery. Combined treatment induced pronounced accumulation of cells in the G0/G1 phase of the cell cycle and increased expression of p53 and p21 Cip1 , accompanied by reduced pRb phosphorylation, consistent with activation of the p53–p21–pRb pathway. OXP+5-FU also increased senescence-associated β-galactosidase (SA-β-Gal) activity, cellular enlargement and flattening, and reactive oxygen species (ROS) production, supporting a senescence-like phenotype. However, after drug withdrawal, treated cells progressively regained proliferative capacity, indicating that the senescence phenotype was transient rather than fully irreversible. Together, these findings show that OXP+5-FU primarily arrests rather than kills LGSOC cells and induces a transient senescence-like phenotype and G0/G1-phase arrest by activating the p53–p21–pRb pathway.

Article activity feed

  1. Oxaliplatin and 5-Fluorouracil induce p53-p21-pRb-associated cell cycle arrest and a transient senescence-like phenotype in patient-derived low-grade serous ovarian cancer cells https://www.biorxiv.org/content/10.64898/2026.09.22.753519v1

  2. Oxaliplatin and 5-Fluorouracil induce p53-p21-pRb-associated cell cycle arrest and a transient senescence-like phenotype in patient-derived low-grade serous ovarian cancer cells https://www.biorxiv.org/content/10.64898/2026.09.22.753519v1